Vaccinogen Inc (VGEN) financial statements (2021 and earlier)

Company profile

Business Address 949 FELL STREET
BALTIMORE, MD 21231
State of Incorp. MD
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments30
Cash and cash equivalents30
Restricted cash and investments00
Inventory, net of allowances, customer advances and progress billings00
Inventory00
Prepaid expense30
Total current assets:60
Noncurrent Assets
Property, plant and equipment00
Intangible assets, net (including goodwill)5663
Intangible assets, net (excluding goodwill)5663
Deferred tax assets, net2 
Other undisclosed noncurrent assets7 
Total noncurrent assets:6563
TOTAL ASSETS:7163
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities34
Accounts payable33
Accrued liabilities 1
Debt 5
Due to related parties 0
Other liabilities1 
Other undisclosed current liabilities214
Total current liabilities:623
Noncurrent Liabilities
Long-term debt and lease obligation3 
Long-term debt, excluding current maturities3 
Liabilities, other than long-term debt1 
Accounts payable and accrued liabilities1 
Other undisclosed noncurrent liabilities9 
Total noncurrent liabilities:13 
Total liabilities:1823
Stockholders' equity
Stockholders' equity attributable to parent5341
Common stock00
Additional paid in capital165144
Accumulated other comprehensive loss(0)(0)
Accumulated deficit(112)(103)
Total stockholders' equity:5341
TOTAL LIABILITIES AND EQUITY:7163

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
Operating expenses(15)(19)
Operating loss:(15)(19)
Nonoperating income (expense)
(Investment Income, Nonoperating)
8(3)
Interest and debt expense(1)(2)
Loss from continuing operations before equity method investments, income taxes:(8)(25)
Other undisclosed loss from continuing operations before income taxes(1) 
Loss from continuing operations before income taxes:(8)(25)
Income tax expense(0) 
Net loss available to common stockholders, basic:(9)(25)
Other undisclosed net loss available to common stockholders, diluted(8) 
Net loss available to common stockholders, diluted:(16)(25)

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
Net loss:(9)(25)
Other comprehensive income (loss)(0)0
Comprehensive loss:(9)(25)
Other undisclosed comprehensive loss, net of tax, attributable to parent (0)
Comprehensive loss, net of tax, attributable to parent:(9)(25)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: